EA201500910A1 - Вакцины против гриппа со сниженным количеством сквалена - Google Patents
Вакцины против гриппа со сниженным количеством скваленаInfo
- Publication number
- EA201500910A1 EA201500910A1 EA201500910A EA201500910A EA201500910A1 EA 201500910 A1 EA201500910 A1 EA 201500910A1 EA 201500910 A EA201500910 A EA 201500910A EA 201500910 A EA201500910 A EA 201500910A EA 201500910 A1 EA201500910 A1 EA 201500910A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- influenza
- virus
- squales
- vaccine
- strain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Вакцины против вируса гриппа включают гемагглютинин по меньшей мере из одного штамма вируса гриппа А и по меньшей мере из одного штамма вируса гриппа В. Они также включают адъювант в виде эмульсии "масло-в-воде" с субмикронными масляными каплями, содержащий сквален. В некоторых вариантах осуществления концентрация гемагглютинина составляет >12 мкг/мл на штамм. В некоторых вариантах осуществления концентрация сквалена составляет <19 мг/мл. В некоторых вариантах осуществления вакцина не содержит ртути. В некоторых вариантах осуществления объем единичной дозы вакцины находится в диапазоне от 0,2 до 0,3 мл. В некоторых вариантах осуществления концентрация сквалена составляет 9,75 мг/мл или 4,88 мг/мл. В некоторых вариантах осуществления вакцина содержит антигены из двух штаммов вируса гриппа А и двух штаммов вируса гриппа В.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20738509P | 2009-02-10 | 2009-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201500910A1 true EA201500910A1 (ru) | 2016-04-29 |
Family
ID=42307898
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500910A EA201500910A1 (ru) | 2009-02-10 | 2010-02-10 | Вакцины против гриппа со сниженным количеством сквалена |
EA201171033A EA023662B1 (ru) | 2009-02-10 | 2010-02-10 | Вакцины против гриппа со сниженным количеством сквалена |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201171033A EA023662B1 (ru) | 2009-02-10 | 2010-02-10 | Вакцины против гриппа со сниженным количеством сквалена |
Country Status (12)
Country | Link |
---|---|
US (3) | US9278126B2 (ru) |
EP (2) | EP2396032B1 (ru) |
JP (3) | JP5642712B2 (ru) |
KR (1) | KR101825697B1 (ru) |
CN (2) | CN105727281A (ru) |
AU (3) | AU2010212550B2 (ru) |
CA (1) | CA2751379C (ru) |
DK (1) | DK2396032T3 (ru) |
EA (2) | EA201500910A1 (ru) |
ES (1) | ES2608841T3 (ru) |
PL (1) | PL2396032T3 (ru) |
WO (1) | WO2010092479A2 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
US11707520B2 (en) * | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
PL2396032T3 (pl) * | 2009-02-10 | 2017-05-31 | Seqirus UK Limited | Szczepionki przeciw grypie o obniżonych zawartościach skwalenu |
WO2011141819A1 (en) † | 2010-05-12 | 2011-11-17 | Novartis Ag | Improved methods for preparing squalene |
CN104043119B (zh) * | 2013-03-13 | 2016-05-25 | 上海医药工业研究院 | 一种新型疫苗佐剂及其制备方法 |
US10872313B2 (en) | 2015-06-02 | 2020-12-22 | ROCA Medical Ltd. | Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy |
US20170304429A1 (en) * | 2014-09-26 | 2017-10-26 | Seqirus UK Limited | Vaccination of immunocompromised subjects |
US10548974B2 (en) * | 2015-06-02 | 2020-02-04 | ROCA Medical Ltd. | Therapeutic treatment kit for allergies based on DNA profiles |
RU2740751C1 (ru) * | 2019-08-28 | 2021-01-20 | Общество с ограниченной ответственностью "Развитие БиоТехнологий" | Способ получения тетравалентной субъединичной противогриппозной вакцины |
CN117582491A (zh) * | 2024-01-18 | 2024-02-23 | 江苏瑞科生物技术股份有限公司 | 流感疫苗组合物及其制备方法和应用 |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4500513A (en) | 1979-05-15 | 1985-02-19 | Miles Laboratories, Inc. | Influenza vaccine production in liquid cell culture |
CA1122527A (en) | 1979-05-15 | 1982-04-27 | Karen K. Brown | Influenza vaccine production in liquid cell culture |
JPS62201573A (ja) | 1986-02-27 | 1987-09-05 | Shionogi & Co Ltd | 家禽用インフルエンザワクチン |
GB8703696D0 (en) | 1987-02-18 | 1987-03-25 | Oxford J S | Influenza vaccine |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
CA2089562A1 (en) | 1990-08-14 | 1992-02-15 | Lex M. Cowsert | Inhibition of influenza virus type a, ann arbor strain h2n2 by antisense oligonucleotides |
JP3755890B2 (ja) | 1992-06-25 | 2006-03-15 | スミスクライン・ビーチャム・バイオロジカルス(ソシエテ・アノニム) | アジュバント含有ワクチン組成物 |
EP0812593B8 (en) | 1993-03-23 | 2010-11-10 | SmithKline Beecham Biologicals S.A. | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
ES2370937T3 (es) | 1993-09-13 | 2011-12-23 | Protein Sciences Corporation | Un método para producir vacunas antigripales polivalentes a base de hemaglutinina. |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
ATE429246T1 (de) | 1994-11-10 | 2009-05-15 | Baxter Healthcare Sa | Verfahren zur herstellung von biologischen produkten in protein-freiem kultur |
UA56132C2 (ru) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
GB9620795D0 (en) | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
JP2000512263A (ja) | 1995-10-20 | 2000-09-19 | イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム | インフルエンザワクチン |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
EP1537877A3 (en) | 1996-10-11 | 2005-08-03 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
AT405939B (de) | 1997-02-24 | 1999-12-27 | Immuno Ag | Verfahren zur inaktivierung von lipidumhüllten viren |
EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
JP4426091B2 (ja) | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
WO1999027961A1 (en) | 1997-12-02 | 1999-06-10 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
DE19803453A1 (de) | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
ES2296390T3 (es) | 1998-05-07 | 2008-04-16 | Corixa Corporation | Composicion coadyuvante y procedimiento para su uso. |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
AU750587B2 (en) | 1998-10-16 | 2002-07-25 | Smithkline Beecham Biologicals (Sa) | Adjuvant systems and vaccines |
EP1574210B1 (en) | 1999-02-26 | 2016-04-06 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with adsorbed macromolecules |
EP1820853B1 (en) | 1999-04-06 | 2011-09-21 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses for vaccines and gene therapy |
DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
DE122007000061I2 (de) | 1999-07-14 | 2011-07-21 | Sinai School Medicine | In vitro-rekonstitution von segmentierten negativstrang-rna-viren. |
CN1391483A (zh) | 1999-09-24 | 2003-01-15 | 史密丝克莱恩比彻姆生物有限公司 | 作为佐剂的聚氧乙烯脱水山梨醇酯和辛苯昔醇组合及其在疫苗中的应用 |
WO2001021152A1 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
AU764368B2 (en) | 1999-09-24 | 2003-08-14 | Smithkline Beecham Biologicals (Sa) | Intranasal influenza virus vaccine |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20040109874A1 (en) | 1999-11-10 | 2004-06-10 | Powderject Vaccines, Inc. | Induction of mucosal immunity by vaccination via the skin route |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
ATE473272T1 (de) | 2000-03-03 | 2010-07-15 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
EP1276468A1 (fr) | 2000-04-26 | 2003-01-22 | Biovector Therapeutics S.A. | Utilisation de vecteurs particulaires dans l' immunomodulation |
WO2001083794A2 (en) | 2000-04-28 | 2001-11-08 | St. Jude Children's Research Hospital | Dna transfection system for the generation of infectious influenza virus |
FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
ATE376059T1 (de) | 2000-06-23 | 2007-11-15 | Wyeth Corp | Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps) |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
NZ525320A (en) | 2000-10-18 | 2004-10-29 | Glaxosmithkline Biolog S | Combinations of immunostimulatory oligonucleotides (CpG), saponin and optionally lipopolysaccharides as potent vaccine adjuvants |
US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
US20040071734A1 (en) | 2001-02-23 | 2004-04-15 | Nathalie Garcon | Novel vaccine |
US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
US20020193729A1 (en) | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
CN1253220C (zh) | 2001-06-29 | 2006-04-26 | 贝克顿迪肯森公司 | 通过微管在真皮内输入疫苗和基因治疗剂 |
US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
CN100360558C (zh) | 2002-06-11 | 2008-01-09 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
EP1594536B1 (en) | 2003-01-30 | 2009-03-25 | Novartis Vaccines and Diagnostics, Inc. | Adjuvanted influenza vaccine |
US20040223976A1 (en) | 2003-03-07 | 2004-11-11 | Elisabetta Bianchi | Influenza virus vaccine |
DE602004029657D1 (de) | 2003-03-24 | 2010-12-02 | Intercell Ag | Verbesserte impfstoffe |
JP2006521321A (ja) | 2003-03-24 | 2006-09-21 | インターツェル・アクチェンゲゼルシャフト | 免疫応答を促進するためのミョウバンおよびTh1免疫応答誘起アジュバントの使用 |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
US20050123550A1 (en) | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
EP1633312A4 (en) | 2003-06-16 | 2012-09-26 | Medimmune Llc | INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS |
US7371395B2 (en) | 2003-07-24 | 2008-05-13 | Merial Limited | Vaccine formulations |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
CA2559371C (en) | 2004-03-09 | 2014-07-08 | Chiron Corporation | Influenza virus vaccines |
JP2007530680A (ja) | 2004-04-01 | 2007-11-01 | アルザ・コーポレーシヨン | インフルエンザワクチンの経皮デリバリーのための装置および方法 |
JP5393978B2 (ja) | 2004-04-05 | 2014-01-22 | ゾエティス・ピー・エルエルシー | マイクロ流動化された水中油型乳剤及びワクチン組成物 |
WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
JP2007537760A (ja) | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
CA2568020C (en) | 2004-05-25 | 2015-04-07 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
DE602005025342D1 (de) | 2004-05-28 | 2011-01-27 | Glaxosmithkline Biolog Sa | Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans |
CA2890962A1 (en) | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | Decreasing potential iatrogenic risks associated with influenza vaccines |
WO2006060710A2 (en) | 2004-12-02 | 2006-06-08 | Becton, Dickinson And Company | Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents |
ES2526170T3 (es) | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
AU2005318087B2 (en) | 2004-12-24 | 2011-04-21 | Abbott Biologicals B.V. | Rescue of influenza virus |
US20080009455A9 (en) | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
CA2600730C (en) | 2005-03-08 | 2014-11-25 | Medimmune, Inc. | Influenza hemagglutinin and neuraminidase variants |
NZ561823A (en) | 2005-03-23 | 2010-04-30 | Glaxosmithkline Biolog Sa | Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
US7384642B2 (en) | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
US7425336B2 (en) | 2005-08-25 | 2008-09-16 | Mevial Limited | Canine influenza vaccines |
EP1945253A2 (en) | 2005-11-04 | 2008-07-23 | Novartis Vaccines and Diagnostics S.r.l. | Adminstration routes for priming/boosting with influenza vaccines |
CN101370515A (zh) * | 2005-11-04 | 2009-02-18 | 诺华疫苗和诊断有限公司 | 包含颗粒佐剂和免疫增强剂组合的流感疫苗 |
US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
JP5005700B2 (ja) | 2005-11-04 | 2012-08-22 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アルミニウムアジュバントに即座に吸着されるインフルエンザワクチン |
ATE513561T1 (de) | 2005-11-04 | 2011-07-15 | Novartis Vaccines & Diagnostic | Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien |
CN102727885A (zh) | 2005-11-04 | 2012-10-17 | 诺华疫苗和诊断有限公司 | 包含颗粒佐剂和免疫增强剂组合的流感疫苗 |
WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
WO2007144772A2 (en) | 2006-06-15 | 2007-12-21 | Novartis Ag | Adjuvant-sparing multi-dose influenza vaccination regimen |
CA3016948A1 (en) | 2006-09-11 | 2008-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
BRPI0717219B8 (pt) * | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, e, uso de uma composição imunogênica |
NZ577405A (en) * | 2006-12-06 | 2012-08-31 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
TW200908994A (en) * | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
CA2690196A1 (en) | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Influenza b viruses having alterations in the hemaglutinin polypeptide |
BRPI0816130A2 (pt) | 2007-08-28 | 2015-02-24 | Baxter Int | Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo. |
US8506966B2 (en) * | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
US20120027813A1 (en) | 2008-02-22 | 2012-02-02 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines for pediatric use |
PL2396032T3 (pl) * | 2009-02-10 | 2017-05-31 | Seqirus UK Limited | Szczepionki przeciw grypie o obniżonych zawartościach skwalenu |
US20120093860A1 (en) | 2009-02-10 | 2012-04-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
FI2638895T3 (fi) | 2009-12-03 | 2024-06-20 | Seqirus Uk Ltd | Ainesosien kierrätys emulsioiden homogenisoinnin aikana |
EP2545172B2 (en) | 2010-03-08 | 2017-12-06 | Novartis AG | Methods of testing for intracellular pathogens |
-
2010
- 2010-02-10 PL PL10710427T patent/PL2396032T3/pl unknown
- 2010-02-10 EP EP10710427.5A patent/EP2396032B1/en active Active
- 2010-02-10 EP EP16190555.9A patent/EP3173097A3/en active Pending
- 2010-02-10 EA EA201500910A patent/EA201500910A1/ru unknown
- 2010-02-10 CN CN201610091730.6A patent/CN105727281A/zh active Pending
- 2010-02-10 CA CA2751379A patent/CA2751379C/en active Active
- 2010-02-10 JP JP2011548806A patent/JP5642712B2/ja active Active
- 2010-02-10 EA EA201171033A patent/EA023662B1/ru not_active IP Right Cessation
- 2010-02-10 KR KR1020117020864A patent/KR101825697B1/ko active IP Right Grant
- 2010-02-10 DK DK10710427.5T patent/DK2396032T3/en active
- 2010-02-10 AU AU2010212550A patent/AU2010212550B2/en active Active
- 2010-02-10 WO PCT/IB2010/000312 patent/WO2010092479A2/en active Application Filing
- 2010-02-10 US US13/148,939 patent/US9278126B2/en active Active
- 2010-02-10 ES ES10710427.5T patent/ES2608841T3/es active Active
- 2010-02-10 CN CN2010800078877A patent/CN102307590A/zh active Pending
-
2014
- 2014-04-22 JP JP2014087975A patent/JP6141576B2/ja active Active
-
2016
- 2016-01-27 US US15/007,719 patent/US10149901B2/en active Active
- 2016-06-08 AU AU2016203830A patent/AU2016203830B2/en active Active
- 2016-08-12 JP JP2016158453A patent/JP2016190877A/ja active Pending
-
2018
- 2018-03-21 AU AU2018202029A patent/AU2018202029A1/en not_active Abandoned
-
2019
- 2019-06-26 US US16/452,783 patent/US11246921B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201500910A1 (ru) | Вакцины против гриппа со сниженным количеством сквалена | |
EA200901161A1 (ru) | Вакцина против гриппа в виде эмульсии типа "масло в воде" | |
AR052625A1 (es) | Nueva composicion | |
EA200801250A1 (ru) | Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе, в качестве адъюванта сплит вакцин против гриппа | |
EP2377552A3 (en) | Influenza vaccines with reduced amount of emulsion adjuvant | |
EA200900024A1 (ru) | Противогриппозная вакцина | |
EA200900784A1 (ru) | Вакцины, включающие антиген из четырех штаммов вируса гриппа | |
JP2011504486A5 (ru) | ||
DK2268823T3 (da) | Fremstilling af squalen ud fra hyperproducerende gærarter | |
AR061894A1 (es) | Vacunas para malaria | |
AR083361A1 (es) | Forma de dosificacion de rapida disolucion de vacuna oral utilizando almidon | |
EA201001478A1 (ru) | Вакцина | |
RU2014140168A (ru) | Улучшенная вакцинация против гриппа | |
NZ580603A (en) | Intradermal influenza vaccine | |
Ng et al. | Lipopeptide vaccines illustrate the potential role of subtype‐crossreactive T cells in the control of highly virulent influenza | |
CO6511241A2 (es) | Régimen de inmunizaión por sensibilización-refuerzo heteróloga | |
BR112012022680A2 (pt) | métodos para proteger um animal um canino contra doença, e, uso de uma vacina contra vírus da influenza canina | |
UA91701C2 (ru) | Мультивалентная иммуногенная композиция против гриппа, которая включает антиген вируса гриппа и адъювант на основе эмульсии масла-в-воде | |
UY29430A1 (es) | Nuevas composiciones inmunogénicas multivalentes contra la gripe, sus usos y procedimientos de preparación. | |
RU2015128294A (ru) | Эмульсия, содержащая неживую лекарственную субстанцию | |
EA200702077A1 (ru) | Вакцина | |
Babapoor Dighaleh | Studies on Nanoparticle Based Avian Influenza Vaccines to Present Immunogenic Epitopes of the Virus with Concentration on Ectodomain of Matrix 2 (M2e) Protein | |
Beal | Vaccine Strategies for Protecting Mammals and Chickens from Influenza Infection using Liposomal M2e and NP Plasmid Vaccines | |
Saperi | Effect of a CpG Adjuvant (TLR9 agonist) on the Efficacy of a Liposomal Influenza M2e Vaccine | |
Khazeni | Expanded vaccination for bird flu worth the investment |